CEACAM5 and inflammatory bowel disease: To this end, various models of genetically engineered CAR Tregs have been developed for the treatment of IBD using three different antigens upregulated in patients with IBD, including CEA-specific, Flagellin-specific CAR Tregs and IL23R-CAR Tregs.